T Cells and Cerebral Ischemic Stroke

Stroke results in cerebral inflammation that causes brain injury and triggers immunodepression, resulting in an increased incidence of morbidity and mortality secondary to remote infection. It is well known that T cells modulate brain inflammation after ischemic stroke, and targeting T cells may be an innovative therapeutic strategy for stroke treatment. T cell deficiency is neuro-protective, but the observed protective effects differ between ischemic models. Recent studies suggest different T cell subsets may have distinct effects on the injured brain. In addition to their role in cerebral inflammation, T cells also play a role in stroke-induced immunodepression. Therefore, T cell-targeted therapies designed to provide protection against brain inflammation might paradoxically contribute to remote organ infection and mortality. Further investigations are required to determine the role of specific T cell subsets in cerebral inflammation and stroke-induced immunodepression, the optimal therapeutic window for treatment, and the appropriate dose of anti-T cell therapy.